Hook & thesis
Globus Medical (GMED) has quietly delivered seven consecutive quarters of margin expansion while growing revenue and free cash flow. At $86.42 the market is not giving the company much credit for that improving profitability or for strategic moves such as the acquisition of Nevro in 04/03/2025 and steady product launches. My thesis: the combination of durable margin expansion, no net debt, and large free cash flow makes GMED a setup for multiple expansion. This is a tactical long with a measured stop and a price target near the stock's 52-week high.
Why the market should care
Globus Medical is a musculoskeletal device company that sells spine and other orthopedics implants and systems. Two things matter for valuation here: margin profile and cash conversion. Over the last seven reported quarters the company has expanded margins consistently. That trend, if it continues, turns a mid-teens-margin medical device business into a company deserving a higher multiple than the low-20s P/E the market is currently applying.
Numbers matter. The company shows earnings per share of $3.99 and trades at a price-to-earnings ratio of roughly 21.68. Enterprise value is about $11.10B while market capitalization sits at $11.60B. Free cash flow for the latest period is $755,590,000 and the company reports cash on the balance sheet of $1.06B with effectively zero debt. The result is a clean capital structure that supports buybacks, M&A or continued product investment without leverage risk.
Business snapshot and fundamental driver
Globus sells Innovative Fusion and Disruptive Technology products across the U.S. and international markets. Recent product expansion includes the COHERE ALIF Spacer and Modulus ALIF Blades launched in 03/11/2025, and in 04/03/2025 management closed the acquisition of Nevro - adding a chronic pain therapy franchise. Management turnover was announced on 07/21/2025 with Keith Pfeil promoted to CEO; leadership continuity and fresh CFO oversight can be constructive for execution if the team delivers against margin targets.
Why should investors care? The orthopedic and spinal implant markets are growing. Several industry reports included in recent news note mid-single-digit to high-single-digit CAGRs for spinal implants and related markets. GMED's combination of organic product launches and targeted M&A positions it to capture both implant growth and adjacent therapy growth. More importantly for investors, the company is showing consistent margin improvement which converts revenue growth into earnings and cash at a faster pace.
Supporting data points
- Current price: $86.42 (previous close $86.44).
- EPS: $3.99; P/E: 21.68.
- Free cash flow: $755,590,000; Enterprise value: $11,097,854,846.
- Balance sheet: Cash roughly $1.06B, debt-to-equity reported as 0.
- Profitability: Return on assets ~ 9.76%; Return on equity ~ 11.23%.
- Liquidity: Current ratio 4.62, quick ratio 2.93.
Those numbers tell a simple story: GMED generates meaningful cash, carries no material leverage, and has improved margins enough to be pushing earnings and free cash flow per share higher. That should support a higher multiple than what the market currently allows, especially if revenue growth remains in the mid-single digits or better thanks to new products and the Nevro footprint.
Valuation framing
The share price implies a market capitalization around $11.6B and an EV-to-sales roughly 3.53x at current levels. With EPS at $3.99 and the stock trading near $86, the market has priced in steady-but-unspectacular execution. But this valuation understates a few factors: the company has $755M in free cash flow that can be allocated to shareholder returns or organic growth; management has a clean balance sheet to pursue accretive M&A; and continued margin expansion would push EPS materially higher without proportionate revenue growth. In short, if margins continue to improve the existing P/E band can expand or EPS can rise enough to justify a higher price.
Catalysts (2-5)
- Continued quarterly margin expansion - management has a track record of seven straight quarters; another quarter or two of improvement should start moving consensus estimates and re-rate the multiple.
- Integration benefits and revenue contribution from Nevro - as the acquisition is digested (closed 04/03/2025), investors will look for cross-sell and cost synergy evidence.
- New product adoption - recent launches (COHERE ALIF Spacer, Modulus ALIF Blades) and any future U.S. or international rollouts that accelerate unit growth.
- Industry tailwinds - a growing spinal implants market and rising adoption of AI-assisted surgery and improved implants could increase addressable market share.
Trade plan (entry, stop, target and horizon)
This is a long trade sized for a disciplined swing to position investor. My trade mechanics:
- Entry price: $86.42 (current quote).
- Stop loss: $78.00. If the stock breaches $78 it would signal a meaningful break below the 50-day area and argue the margin story is priced out or execution is slipping.
- Target price: $100.00. This reflects both multiple expansion toward the high-teens/low-20s on higher EPS and the stock reclaiming its recent 52-week high neighborhood.
- Horizon: long term (180 trading days). I want time for at least two reported quarters of results and for M&A/product integration to translate to visible earnings and cash flow improvements.
Rationale for the horizon: margin expansion and integration benefits are multi-quarter processes. A 180 trading day horizon (~9 calendar months) allows earnings revisions, visible cash flow outcomes, and potential re-rating if management continues execution.
Technical and market positioning notes
Momentum and technical signals are constructive. The 10-day SMA sits near $84.43, 20-day SMA near $81.70 and 50-day SMA near $80.24 - the price is above those averages and 9- and 21-day EMAs point higher. Short interest has risen at different points recently (settlement 07/31/2026 short interest ~ 6,886,644 shares, days to cover ~ 4.89) and there has been elevated short volume in several sessions. That dynamic can amplify a re-rating on better-than-expected results or positive headlines.
Risks and counterarguments (at least 4)
- Execution risk - margin expansion has to be defended. If costs re-accelerate or new products fail to gain adoption, margins can compress quickly and EPS guidance may be cut.
- Integration risk from Nevro - acquisitions can be dilutive if synergies are slower to materialize or if the acquired business underperforms. Integration noise could depress multiple in the near-term.
- Reimbursement and regulatory risk - changes to reimbursement for spinal procedures or any regulatory setbacks on new products could materially affect sales and margins.
- Macro and procedure volumes - elective procedure volumes are sensitive to economic conditions. A slowdown could reduce demand for implants and slow revenue growth.
- Counterargument: the market's conservative multiple could be warranted if the margin expansion is cyclical rather than structural - for example, one-off cost cuts or temporary product mix changes. If investors believe that expansion won't persist, the stock may remain rangebound despite strong recent cash flow.
What would change my mind
I would reconsider this bullish stance if we see any of the following: a missed quarter where revenue or margin guidance is materially lowered; evidence that Nevro is materially underperforming expectations or creating persistent integration costs; or a sudden shift in procedure volume trends that meaningfully dents the top line. Conversely, faster-than-expected margin improvement, clear synergy capture from the Nevro deal, or sustained acceleration in international sales would strengthen the bullish case and prompt moving the target higher.
Conclusion
Globus Medical is an earnings and cash flow story more than a rapid top-line growth story. The company has shown seven quarters of margin expansion, generates roughly $755M of free cash flow, carries no net debt and has a market cap near $11.6B. At $86.42 the market is not fully rewarding the sustained operational improvement. For investors willing to give management time - and who can tolerate M&A and procedure volume risk - this is a measured long trade: entry $86.42, stop $78.00, target $100.00 on a long-term horizon of 180 trading days. Watch margins, integration metrics and procedure volumes closely; they will determine whether the market eventually gives GMED the multiple it deserves.